Hypertrophic cardiomyopathy: Difference between revisions
m (→Management:) |
|||
| Line 55: | Line 55: | ||
*'''Asymptomatic patients:''' [[Hypertrophic cardiomyopathy in special clinical scenarios|Asymptomatic patients]] | *'''Asymptomatic patients:''' [[Hypertrophic cardiomyopathy in special clinical scenarios|Asymptomatic patients]] | ||
*'''Symptomatic patints:''' [[Hypertrophic cardiomyopathy medical treatment|Pharmacologic Management]] | [[Hypertrophic cardiomyopathy interventional cardiology|Invasive Therapies]] | [[Hypertrophic cardiomyopathy interventional cardiology|Pacing]] | [[Hypertrophic cardiomyopathy interventional cardiology|Selection of Patients for ICDs]] | [[Hypertrophic cardiomyopathy interventional cardiology|Selection of ICD-Device type]] | [[Hypertrophic cardiomyopathy surgical treatment#Cardiac transplantation|Selection of Patients for Heart Transplantation]] | *'''Symptomatic patints:''' [[Hypertrophic cardiomyopathy medical treatment|Pharmacologic Management]] | [[Hypertrophic cardiomyopathy interventional cardiology|Invasive Therapies]] | [[Hypertrophic cardiomyopathy interventional cardiology#Alcohol septal ablation|Alcohol septal ablation]] | [[Hypertrophic cardiomyopathy interventional cardiology#Septal Myectomy|Septal Myectomy]] | [[Hypertrophic cardiomyopathy interventional cardiology|Pacing]] | [[Hypertrophic cardiomyopathy interventional cardiology|Selection of Patients for ICDs]] | [[Hypertrophic cardiomyopathy interventional cardiology|Selection of ICD-Device type]] | [[Hypertrophic cardiomyopathy surgical treatment#Cardiac transplantation|Selection of Patients for Heart Transplantation]] | ||
*'''Special Clinical Scenarios:''' [[Hypertrophic cardiomyopathy in special clinical scenarios|Patients With LV Systolic Dysfunction]] | [[Hypertrophic cardiomyopathy risk factors for sudden death|Sudden cardiac death Risk Stratification]] | [[Hypertrophic cardiomyopathy medical treatment#Avoid strenuous Activity|Participation in Competitive or Recreational Sports and Physical Activity]] | [[Hypertrophic cardiomyopathy medical treatment|Management of Atrial Fibrillation]] | [[Hypertrophic cardiomyopathy in special clinical scenarios|Pregnancy/Delivery]] | *'''Special Clinical Scenarios:''' [[Hypertrophic cardiomyopathy in special clinical scenarios|Patients With LV Systolic Dysfunction]] | [[Hypertrophic cardiomyopathy risk factors for sudden death|Sudden cardiac death Risk Stratification]] | [[Hypertrophic cardiomyopathy medical treatment#Avoid strenuous Activity|Participation in Competitive or Recreational Sports and Physical Activity]] | [[Hypertrophic cardiomyopathy medical treatment|Management of Atrial Fibrillation]] | [[Hypertrophic cardiomyopathy in special clinical scenarios|Pregnancy/Delivery]] | ||
Revision as of 21:07, 12 January 2012
For patient information click here
| Hypertrophic cardiomyopathy | |
 | |
|---|---|
| Hypertrophic cardiomyopathy. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology | |
| ICD-10 | I42.1-I42.2 |
| ICD-9 | 425.4 |
| DiseasesDB | 6373 |
| MeSH | D002312 |
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and Related Terms: Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial or idiopathic hypertrophic subaortic stenosis, familial or idiopathic hypertrophic obstructive cardiomyopathy, primitive hypertrophic obstructive cardiomyopathy, primitive hypertrophic subaortic stenosis, muscular subaortic stenosis, apical hypertrophic cardiomyopathy, which is also known as nonobstructive hypertrophic cardiomyopathy and Japanese variant hypertrophic cardiomyopathy or the Yamaguchi variant (since the first cases described were all in individuals of Japanese descent).
Overview
Pathophysiology
Genetics | Histopathologic Abnormalities | Anatomic Abnormalities | Outflow Obstruction | Ischemia | Arrhythmogenesis
Epidemiology and Demographcis
Screening
Differential Diagnosis
Natural History, Prognosis and Sudden Cardiac Death Risk
Diagnosis
History and Symptoms | Physical examination | Electrocardiogram | Echocardiography | Cardiac MRI | Cardiac CT | Positron Emission Tomography | Cardiac Catheterization | Electrophysiologic study | Pathological Findings
Treatment
Medical treatment | Interventional Cardiology and Device Based Therapy | Surgical treatment | Treatment strategy
Special Patient Populations
Hypotension/Cardiovascular collapse | Pregnancy
2011 ACCF/AHA Guideline Recommendations
Screening:
Genetic Testing Strategies / Family Screening | Genotype-Positive / Phenotype-Negative Patients
Diagnostic testing:
Electrocardiogram | Echocardiography | Stress Echocardiography | Stress Testing | Cardiac Magnetic Resonance | Cardiac CT | Positron Emission Tomography
Management:
- Asymptomatic patients: Asymptomatic patients
- Symptomatic patints: Pharmacologic Management | Invasive Therapies | Alcohol septal ablation | Septal Myectomy | Pacing | Selection of Patients for ICDs | Selection of ICD-Device type | Selection of Patients for Heart Transplantation
- Special Clinical Scenarios: Patients With LV Systolic Dysfunction | Sudden cardiac death Risk Stratification | Participation in Competitive or Recreational Sports and Physical Activity | Management of Atrial Fibrillation | Pregnancy/Delivery
Guideline Resources
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy [1][2]
External links
- Hypertrophic Cardiomyopathy Association
- Cardiomyopathy Association
- Hypertrophic Cardiomyopathy Research Foundation
References
- ↑ Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 58 (25): 2703–38. doi:10.1016/j.jacc.2011.10.825. PMID 22075468. Retrieved 2011-12-19. Unknown parameter
|month=ignored (help) - ↑ Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 58 (25): e212–60. doi:10.1016/j.jacc.2011.06.011. PMID 22075469. Retrieved 2011-12-19. Unknown parameter
|month=ignored (help)